Alle Studien
Aktiv, aber nicht rekrutierendPHASE1INTERVENTIONELL

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

This study is for adult patients diagnosed with a type of brain tumour called glioma, specifically when previous treatments haven't been successful. The main goal is to figure out the highest dose of a new experimental drug, BI 764532, that people can safely take. This drug is designed to help your body's immune system recognise and attack the cancer cells. Participants will receive BI 764532 through a drip. They will have regular check-ups at the study site, especially at the start, to make sure the treatment is safe and to monitor any side effects. If the treatment seems to be helping and is well-tolerated, participants can continue with it, with the number of visits depending on how they respond.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE1
Sponsor
Boehringer Ingelheim
Einschreibeziel
20
Starten
30. Jan 2024
Geschätzte Fertigstellung
30. Sep 2027

Worum geht es in dieser Studie?

This study, known as 1438-0003, is looking for adult patients who have a type of brain tumour called glioma. This particular study is for people whose tumour has a specific marker called DLL3, and for whom standard treatments haven't worked.

The main purpose of this study is to find the best and safest dose of a new medicine called BI 764532. This medicine is special because it acts like a bridge, connecting your body's immune cells (called T-cells) directly to the cancer cells. The idea is that by linking them together, your immune system will be better at finding and destroying the cancer. This is a very early-stage study, meaning it's one of the first times this drug is being tested in people.

Participants will receive BI 764532 through an intravenous drip (into a vein). Initially, they will need to stay at the study site so doctors can closely watch how they react to the treatment and ensure their safety. If the treatment is helping and isn't causing too many side effects, participants can continue with it. The number of times they need to visit the study site will depend on how their body responds to the medicine.

Wichtige Erkenntnisse

  • This study is for adults with a specific type of brain tumour (glioma) where other treatments haven't worked.
  • It's testing a new drug (BI 764532) to see its safest and most effective dose.
  • The drug aims to help your own immune system fight the cancer.
  • You will receive the drug through a drip and have regular check-ups.
  • Your safety and any side effects will be closely monitored throughout the study.

Wer könnte berechtigt sein?

To be considered for this study, you must be 18 years old or older. You will need to provide your clear agreement to take part after understanding what the study involves. Doctors will need to confirm you have a brain tumour (glioma) that couldn't be controlled by previous treatments, and that your tumour shows a marker called DLL3. Your general health and ability to carry out daily activities will also be checked.

There are also some reasons why you might not be able to join. For example, if you've already been part of this specific trial or another drug trial at the same time. You also can't have cancer spread beyond your brain in certain ways, or have recently received certain types of cancer treatments or radiotherapy.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Have you been diagnosed with a primary progressive diffuse glioma?
  3. Have previous treatments for your glioma not been successful?
  4. Do doctors know that your tumour has the DLL3 marker?
  5. Are you generally able to carry out your daily activities well?
  6. Have you NOT had certain other cancer treatments very recently?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, you will receive the new medicine, BI 764532, through a drip into your bloodstream. When you first start treatment, you'll need to stay at the study site so the doctors and nurses can carefully watch you for any reactions or side effects. You will have regular appointments at the study site. These visits will involve various health checks, blood tests, and scans to see how you are responding to the treatment and if you are experiencing any unwanted effects. The exact number of visits and how long they last will depend on how your body reacts to the medicine and if it's helping. If the treatment is beneficial and you tolerate it well, you can continue with it. You can withdraw from the study at any time.

Potenzielle Risiken und Vorteile

Like all medical studies, there are potential benefits and risks. While this new treatment might help control your brain tumour, there's no guarantee it will work for everyone, as it's an early-stage study. There could be side effects from the drug, which doctors will closely monitor. You will be told about all known possible risks before you decide to join. It is very important to remember that you are free to leave the study at any time, for any reason, without it affecting your future medical care.

Standorte (12)

  • Universität von Kalifornien Irvine
    Verifizierte Postleitzahl
    Orange, Vereinigte Staaten
  • SCRI Oncology Partners
    Verifizierte Postleitzahl
    Nashville, Vereinigte Staaten
  • Salzburg Cancer Research Institute
    Verifizierte Postleitzahl
    Salzburg, Österreich
  • Universitätsklinikum Frankfurt
    Verifizierte Postleitzahl
    Frankfurt, Deutschland
  • Klinikum der Universität München AÖR
    Verifizierte Postleitzahl
    München, Germany
  • Universitätsklinikum Tübingen
    Verifizierte Postleitzahl
    Tübingen, Germany
  • Erasmus Medisch Centrum-ROTTERDAM-50697
    Verifizierte Postleitzahl
    Rotterdam, Niederlande
  • Hospital del Mar
    Verifizierte Postleitzahl
    Barcelona, Spanien
  • Hospital Universitario 12 de Octubre
    Verifizierte Postleitzahl
    Madrid, Spanien
  • Cantonal Hospital of Aarau
    Verifizierte Postleitzahl
    Aarau, Switzerland
  • University Hospital of Lausanne
    Verifizierte Postleitzahl
    Lausanne, Switzerland
  • University Hosp. Zurich
    Verifizierte Postleitzahl
    Zürich, Schweiz

Häufige Fragen

What is a glioma?

A glioma is a common type of tumour that starts in the brain or spinal cord. This study specifically focuses on certain types of these tumours.

What does DLL3 positive mean?

DLL3 is a specific marker that can be found on some cancer cells. For this study, your tumour must have this marker for you to be eligible.

What is BI 764532?

BI 764532 is a new experimental drug designed to help your body's immune system find and fight cancer cells that have the DLL3 marker.

Why are they looking for the 'highest dose I can tolerate'?

In early studies, doctors need to carefully find the dose that is most effective at fighting the cancer while also being safe and manageable for patients, with the fewest side effects.

Will I have to stay in the hospital?

Initially, when you start the treatment, you will need to stay at the study site or hospital so that doctors can closely watch you for any reactions or side effects to the new medicine.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.